Eli Lilly Surges On Promising Data From Late-Stage Alzheimer's Drug Trial
"This is the first Phase 3 trial of any investigational medicine for Alzheimer's disease to deliver 35% slowing of clinical and functional decline," Eli Lilly said. Eli Lilly (LLY)…
